
We are pleased to announce a strategic collaboration with @ImmunoGenesis_ to accelerate the clinical development of IMGS-001, a novel cytotoxic dual checkpoint inhibitor targeting PD-L1 and PD-L2. This partnership integrates BostonGene’s AI-driven multiomics and high-resolution spatial biology into the Phase 1a/b clinical framework to move beyond conventional monitoring. By leveraging our AI foundation model, this collaboration is designed to elucidate MoA, identify predictive biomarkers and optimize patient selection. Together, we are working to eliminate the "trial and error" approach often associated with immunotherapy. By decoding the precise cellular and molecular pathways driving clinical outcomes, we are ensuring that next-generation therapies reach the patients who need them most with greater speed and clinical certainty. Read more: bostongene.com/news-and-publ…













